Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WJ01024 in advanced cancer
NCT04991129Phase 1Terminated
- Sponsor
- Suzhou Junjing BioSciences
- Start
- Sep 2021
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of WJ01024 in solid tumor (advanced stage) and hematologic malignancy (10 arms), sponsored by Suzhou Junjing BioSciences. Primary endpoint: Incidence of Adverse Events and Serious Adverse Events at 2 years. Started Sep 2021; status: terminated.
02
Drugs
WJ01024
03
Conditions
solid tumor (advanced stage)hematologic malignancy
Beyond the preview
Go deeper on NCT04991129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04991129.